• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5069985)   Today's Articles (51)
For: Canney PA, Machin MA, Curto J. A feasibility study of the efficacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer. Eur J Cancer 2006;42:2751-6. [PMID: 17027257 DOI: 10.1016/j.ejca.2006.08.014] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2006] [Accepted: 08/16/2006] [Indexed: 11/22/2022]
Number Cited by Other Article(s)
1
Zhang X, Chen J, Cheng C, Li P, Cai F, Xu H, Lu Y, Cao N, Liu J, Wang J, Hua ZC, Zhuang H. Aspirin potentiates celecoxib-induced growth inhibition and apoptosis in human non-small cell lung cancer by targeting GRP78 activity. Ther Adv Med Oncol 2020;12:1758835920947976. [PMID: 32994805 PMCID: PMC7502795 DOI: 10.1177/1758835920947976] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2019] [Accepted: 07/13/2020] [Indexed: 12/24/2022]  Open
2
Rasekhian M, Tavallaei O, Marzbany M. Combinational treatments for breast cancer. JOURNAL OF REPORTS IN PHARMACEUTICAL SCIENCES 2020. [DOI: 10.4103/jrptps.jrptps_89_19] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
3
Li J, Hao Q, Cao W, Vadgama JV, Wu Y. Celecoxib in breast cancer prevention and therapy. Cancer Manag Res 2018;10:4653-4667. [PMID: 30464589 PMCID: PMC6208493 DOI: 10.2147/cmar.s178567] [Citation(s) in RCA: 49] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]  Open
4
Cai F, Chen M, Zha D, Zhang P, Zhang X, Cao N, Wang J, He Y, Fan X, Zhang W, Fu Z, Lai Y, Hua ZC, Zhuang H. Curcumol potentiates celecoxib-induced growth inhibition and apoptosis in human non-small cell lung cancer. Oncotarget 2017;8:115526-115545. [PMID: 29383179 PMCID: PMC5777791 DOI: 10.18632/oncotarget.23308] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2017] [Accepted: 12/05/2017] [Indexed: 01/01/2023]  Open
5
Interaction of Salicylates and the Other Nonsteroidal Anti-Inflammatory Agents With Breast Cancer Endocrine Treatment: Systematic Review. Am J Clin Oncol 2016;38:641-4. [PMID: 25503435 DOI: 10.1097/coc.0000000000000166] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
6
Ewes WA, Badr SM, Eisa HM, Nasr MN. Molecular modeling and synthesis of new 1,5-diphenylpyrazoles as breast cancer cell growth inhibitors. HETEROCYCL COMMUN 2015. [DOI: 10.1515/hc-2015-0156] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]  Open
7
Jeon YW, Ahn YE, Chung WS, Choi HJ, Suh YJ. Synergistic effect between celecoxib and luteolin is dependent on estrogen receptor in human breast cancer cells. Tumour Biol 2015;36:6349-59. [PMID: 25851346 DOI: 10.1007/s13277-015-3322-5] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2014] [Accepted: 03/12/2015] [Indexed: 12/17/2022]  Open
8
COX2 expression in high-grade breast cancer: evidence for prognostic significance in the subset of triple-negative breast cancer patients. Med Oncol 2014;31:989. [PMID: 24816739 DOI: 10.1007/s12032-014-0989-1] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2013] [Accepted: 04/28/2014] [Indexed: 12/31/2022]
9
Kim HS, Moon HG, Han W, Yom CK, Kim WH, Kim JH, Noh DY. COX2 overexpression is a prognostic marker for Stage III breast cancer. Breast Cancer Res Treat 2012;132:51-59. [PMID: 21533532 DOI: 10.1007/s10549-011-1521-3] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2011] [Accepted: 04/11/2011] [Indexed: 10/18/2022]
10
Liu B, Wen JK, Li BH, Fang XM, Wang JJ, Zhang YP, Shi CJ, Zhang DQ, Han M. Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms. Cell Death Dis 2011;2:e185. [PMID: 21796157 PMCID: PMC3199716 DOI: 10.1038/cddis.2011.64] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
11
Lustberg MB, Povoski SP, Zhao W, Ziegler RM, Sugimoto Y, Ruppert AS, Lehman AM, Shiels DR, Mrozek E, Ramaswamy B, Layman RM, Brueggemeier RW, Shapiro CL. Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. Clin Breast Cancer 2011;11:221-7. [PMID: 21729671 DOI: 10.1016/j.clbc.2011.03.022] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2010] [Accepted: 03/24/2011] [Indexed: 11/20/2022]
12
Chow LWC, Yip AYS, Chu WP, Loo WTY, Toi M. Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial. J Steroid Biochem Mol Biol 2011;125:112-9. [PMID: 21236344 DOI: 10.1016/j.jsbmb.2010.12.018] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/30/2010] [Revised: 12/28/2010] [Accepted: 12/31/2010] [Indexed: 11/15/2022]
13
Farag AM, Ali KA, El-Debss TM, Mayhoub AS, Amr AGE, Abdel-Hafez NA, Abdulla MM. Design, synthesis and structure–activity relationship study of novel pyrazole-based heterocycles as potential antitumor agents. Eur J Med Chem 2010;45:5887-98. [DOI: 10.1016/j.ejmech.2010.09.054] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2010] [Revised: 09/22/2010] [Accepted: 09/23/2010] [Indexed: 10/19/2022]
14
Glynn SA, Prueitt RL, Ridnour LA, Boersma BJ, Dorsey TM, Wink DA, Goodman JE, Yfantis HG, Lee DH, Ambs S. COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer. BMC Cancer 2010;10:626. [PMID: 21078168 PMCID: PMC2993681 DOI: 10.1186/1471-2407-10-626] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2010] [Accepted: 11/15/2010] [Indexed: 11/30/2022]  Open
15
Byrns MC, Duan L, Lee SH, Blair IA, Penning TM. Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer. J Steroid Biochem Mol Biol 2010;118:177-87. [PMID: 20036328 PMCID: PMC2819162 DOI: 10.1016/j.jsbmb.2009.12.009] [Citation(s) in RCA: 95] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/29/2009] [Revised: 12/15/2009] [Accepted: 12/17/2009] [Indexed: 10/20/2022]
16
Corona G, Elia C, Casetta B, Diana C, Rosalen S, Bari M, Toffoli G. A liquid chromatography-tandem mass spectrometry method for the simultaneous determination of exemestane and its metabolite 17-dihydroexemestane in human plasma. JOURNAL OF MASS SPECTROMETRY : JMS 2009;44:920-928. [PMID: 19214962 DOI: 10.1002/jms.1566] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
17
Baumann KH, Klusmeier E, Eggemann I, Reinartz S, Almeroth A, Kalder M, Wagner U. Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro. BREAST CANCER-BASIC AND CLINICAL RESEARCH 2009;3:23-34. [PMID: 21556247 PMCID: PMC3086307 DOI: 10.4137/bcbcr.s2291] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
18
Falandry C, Canney P, Freyer G, Dirix L. Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Ann Oncol 2009;20:615-20. [DOI: 10.1093/annonc/mdn693] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]  Open
19
Falandry C, Debled M, Bachelot T, Delozier T, Crétin J, Romestaing P, Mille D, You B, Mauriac L, Pujade-Lauraine E, Freyer G. Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. Breast Cancer Res Treat 2008;116:501-8. [DOI: 10.1007/s10549-008-0229-5] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2008] [Accepted: 10/15/2008] [Indexed: 12/20/2022]
20
Chow LWC, Yip AYS, Loo WTY, Lam CK, Toi M. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 2008;111:13-7. [PMID: 18514508 DOI: 10.1016/j.jsbmb.2008.04.004] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/29/2007] [Revised: 04/01/2008] [Accepted: 04/11/2008] [Indexed: 01/22/2023]
21
Perspectives on microbes as oncogenic infectious agents and implications for breast cancer. Med Hypotheses 2008;71:302-6. [PMID: 18445513 DOI: 10.1016/j.mehy.2008.02.016] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2008] [Revised: 02/05/2008] [Accepted: 02/08/2008] [Indexed: 01/13/2023]
22
Dirix LY, Ignacio J, Nag S, Bapsy P, Gomez H, Raghunadharao D, Paridaens R, Jones S, Falcon S, Carpentieri M, Abbattista A, Lobelle JP. Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib. J Clin Oncol 2008;26:1253-9. [PMID: 18323548 DOI: 10.1200/jco.2007.13.3744] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
23
Agrawal A, Fentiman IS. NSAIDs and breast cancer: a possible prevention and treatment strategy. Int J Clin Pract 2008;62:444-9. [PMID: 18194278 DOI: 10.1111/j.1742-1241.2007.01668.x] [Citation(s) in RCA: 84] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]  Open
24
Haffty BG, Yang Q, Moran MS, Tan AR, Reiss M. Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation. Int J Radiat Oncol Biol Phys 2008;71:1006-13. [PMID: 18262731 DOI: 10.1016/j.ijrobp.2007.11.063] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2007] [Revised: 11/15/2007] [Accepted: 11/16/2007] [Indexed: 12/11/2022]
25
Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancer. Breast Cancer 2007;15:73-8. [DOI: 10.1007/s12282-007-0015-y] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
26
Mannello F, Qin W, Zhu W, Fabbri L, Tonti GA, Sauter ER. Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2. Breast Cancer Res Treat 2007;111:209-18. [DOI: 10.1007/s10549-007-9779-1] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2007] [Accepted: 09/27/2007] [Indexed: 02/06/2023]
27
Gligorov J, Azria D, Namer M, Khayat D, Spano JP. Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives. Crit Rev Oncol Hematol 2007;64:115-28. [PMID: 17702596 DOI: 10.1016/j.critrevonc.2007.06.010] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2006] [Revised: 06/25/2007] [Accepted: 06/26/2007] [Indexed: 01/06/2023]  Open
28
Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 2007;7:389-97. [PMID: 17446858 DOI: 10.1038/nrc2127] [Citation(s) in RCA: 199] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA